KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Amortization - Intangibles (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Amortization - Intangibles data on record, last reported at $168.4 million in Q3 2025.

  • For Q3 2025, Amortization - Intangibles rose 6.93% year-over-year to $168.4 million; the TTM value through Sep 2025 reached $646.8 million, up 4.33%, while the annual FY2025 figure was $654.7 million, 4.36% up from the prior year.
  • Amortization - Intangibles reached $168.4 million in Q3 2025 per JAZZ's latest filing, up from $162.1 million in the prior quarter.
  • Across five years, Amortization - Intangibles topped out at $172.1 million in Q1 2022 and bottomed at $68.2 million in Q1 2021.
  • Average Amortization - Intangibles over 5 years is $149.5 million, with a median of $155.1 million recorded in 2023.
  • Peak YoY movement for Amortization - Intangibles: surged 152.37% in 2022, then fell 12.96% in 2023.
  • A 5-year view of Amortization - Intangibles shows it stood at $157.3 million in 2021, then dropped by 12.66% to $137.4 million in 2022, then rose by 10.31% to $151.6 million in 2023, then grew by 4.85% to $158.9 million in 2024, then increased by 5.96% to $168.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization - Intangibles were $168.4 million in Q3 2025, $162.1 million in Q2 2025, and $158.9 million in Q4 2024.